Introducing EDI’s COVID-19 Nucleocapsid IgG Quantitative ELISA Kit
The EDI™ COVID-19 Nucleocapsid IgG Quantitative ELISA Kit is designed, developed & produced for the quantitative measurement of human anti-COVID-19 (anti-SARS-CoV-2) IgG antibody in serum. The test uses a series of calibrators & controls in order to determine a standard curve, which allows for specific, concentration-based results of patient samples, giving researchers & healthcare providers access to quantitative patient data in order to better understand a patient's current disease stage. - October 14, 2020
Epitope Diagnostics Has Proudly Introduced Immunoassay Kits Exclusively for the Qualitative Detection of COVID-19
The EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit and EDI™ Novel Coronavirus COVID-19 IgM ELISA Kits. With proven results from clinical testing in China, Epitope Diagnostics, Inc. is eager to cooperate and collaborate to combat the current COVID-19 situation. - March 06, 2020
Epitope Diagnostics, Inc. Certifies Its Total 25-OH Vitamin D EIA Kit Through the CDC’s Vitamin D Standardization-Certification Program (VDSCP)
Epitope Diagnostics, Inc. (EDI), is pleased to announce it has received certification for the Vitamin D Standardization Program (VDSP) for vitamin D measurement in the EDI™ Total 25-OH Vitamin D EIA Kit. CDC’s Vitamin D Standardization-Certification Program (VDSCP) evaluates the... - October 21, 2018
Epitope Diagnostics, Inc. Joins MetroConnect to Expand International Growth
Epitope Diagnostics, Inc. is pleased to announce it has been selected to take part in MetroConnect 2018, an export assistance program run by the World Trade Center San Diego (WTC) and designed to help San Diego companies accelerate their global growth. This program will allow Epitope Diagnostics... - September 23, 2018
Studies Use Epitope Diagnostics’ ELISA Kit to Establish Chromogranin A as a Potential Prognostic Marker in Prostate Cancer Patients Treated with Antiandrogens
Italian research group uses Epitope Diagnostics' Chromogranin A ELISA kit in study to determine CgA as a potential prognostic marker in castration-resistant prostate cancer patients treated in abiraterone or enzalutamide. - February 11, 2016
Epitope Diagnostics Introduces Novel Fecal NGAL Specific ELISA Kit for Inflammatory Bowel Disease
Epitope Diagnostics introduces its novel fecal neutrophil gelatinase-associated lipocalin (NGAL) ELISA kit. This is the first commercial kit that is developed for measurement of NGAL levels in human stool sample. Fecal NGAL is potentially a better marker than those currently used in clinical practice. - September 01, 2015
Epitope Diagnostics Launches a Novel 25-OH Vitamin D ELISA Kit
Epitope Diagnostics, Inc. has added a new ELISA kit to their product line to detect the total amount of 25-OH vitamin D2 and D3 in serum or plasma sample. This is a monoclonal antibody-based ELISA with a unique vitamin D releasing buffer for easy and reliable measurement of 25-OH vitamin D. - May 11, 2015
Epitope Diagnostics Expands Infectious Disease Product Line with Clostridium Difficile Family of Tests
Epitope Diagnostics, Inc. developed and produced a new ELISA Kit and rapid test with accessories for the detection of Clostridium difficile specific glutamate dehydrogenase (GDH). - May 10, 2015
Epitope Diagnostics, Inc. Introduces New 2-Hour Human ACTH ELISA Kit
Epitope Diagnostics releases a new, highly sensitive and robust human ACTH ELISA kit which can be completed in 2 hours, increasing the efficiency of clinical laboratory operations. - August 19, 2014
Epitope Diagnostics, Inc. Expands Product Panel with New Set of H. Pylori Antigen ELISA Kits and Novel Sample Collection Device
Epitope Diagnostics, Inc. has launched two user-friendly fecal Helicobacter pylori (H. pylori) antigen ELISA kits, along with a new sample collection device. One ELISA assay is qualitative while the other is quantitative, allowing for both the detection and measurement of active H. pylori antigen. H. pylori is a bacterium which causes infectious stomach disease and is linked to stomach cancer. A positive H. pylori antigen test indicates an active infection. - April 22, 2014
Epitope Diagnostics Launches the Second Generation Immunoassay Kits Exclusively for the Quantitative Measurement of Antibody Drug Conjugate (ADC) Levels
Epitope Diagnostics has recently launched second-generation ADC kits exclusively for the quantitative measurement of DM1-, MMAE-, and MMAF-ADC level. These kits measure both humanized monoclonal antibody based ADC and mouse monoclonal antibody based ADC. Additional benefits for testing PK samples from mice are utilized by these second generation kits. - October 12, 2013
Epitope Diagnostics Launches the First Commercially Available Immunoassay Kits Exclusively for the Quantitative Measurement of Antibody Drug Conjugate Level (ADC)
Epitope Diagnostics has proudly introduced immunoassay kits exclusively for the quantitative measurement of antibody drug conjugate level (ADC). These kits include the EDI™ Mertansine (DM1) ADC EIA Kit, EDI™ Monomethylauristatin F (MMAF) ADC EIA Kit, and the EDI™ Monomethylauristatin E (MMAE) ADC EIA Kit. This technology, together with groundbreaking applications such as Genentech's Kadcyla (Ado-Trastuzumab Emtansine), this promising approach may help to clinically monitor cancer treatment. - June 20, 2013
The EDI Human Intact FGF-21 ELISA Kit is the First Immunoassay Kit That Exclusively Measures Human Intact FGF-21
Epitope Diagnostics is pleased to introduce a brand new ELISA kit for the quantitative determination of β-Klotho & FGF Receptor Active Human Intact FGF-21 level in EDTA-plasma or serum. This assay measures human intact FGF-21, instead of FGF-21 fragments like similar commercially available kits on the market today. - May 31, 2013